Clinical Study
A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients
Table 3
Secondary study endpoints-full analysis set.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HCV: hepatitis C virus; SD: standard deviation; HAI: histologic activity index. *95% CI, −0.105 to 0.211%; , Wilcoxon Gehan test. †Worst fibrosis staging per patient using the modified scoring system of Ishak et al. [19] in which a score of 6 is complete fibrosis. Central evaluation of nonprotocol biopsies and protocol biopsies (at 6 and 12 months) was used to assess fibrosis score. ‡ Worst histological HCV grading per patient using the modified HAI grading [14]. Central evaluation of nonprotocol biopsies and protocol biopsies (at 6 and 12 months) was used to assess HAI grading. §95% CI (Greenwood formula) for the difference in 12-month patient survival was −0.227 to −0.019%, . ¶Local evaluation of biopsies. , chi-square test comparing the numbers of patients. |